Vista Pharmaceuticals (BOM:524711) ROCE %: -75.10% (As of Mar. 2026)


BOM:524711 Vista Pharmaceuticals Ltd BOM:524711
47 GF Score
Price ₹7.28
GF Value ₹6.05
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vista Pharmaceuticals ROCE %?

Vista Pharmaceuticals BOM:524711 +0.69% 47 ROCE % is -75.10% as of Mar. 2026. GuruFocus rates BOM:524711 with a GF Score™ of 47/100 and a GF Value™ of ₹6.05 (Modestly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vista Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -75.10%.

Vista Pharmaceuticals  (BOM:524711) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vista Pharmaceuticals ROCE % Related Terms

Vista Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Vista Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vista Pharmaceuticals ROCE % Chart

Vista Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.07 -10.76 -9.23 -9.46 -34.85

Vista Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.14 -10.74 -29.30 -26.39 -75.10
BOM:524711
47GF Score
Vista Pharmaceuticals Ltd BOM:524711
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vista Pharmaceuticals ROCE % Calculation

Vista Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-150.503/( ( (602.895 - 123.658) + (550.822 - 166.464) )/ 2 )
=-150.503/( (479.237+384.358)/ 2 )
=-150.503/431.7975
=-34.85 %

Vista Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-288.644/( ( (0 - 0) + (550.822 - 166.464) )/ 1 )
=-288.644/( ( 0 + 384.358 )/ 1 )
=-288.644/384.358
=-75.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -75.10% mean?
Vista Pharmaceuticals (BOM:524711) has a ROCE % of -75.10% as of Mar. 2026.
Is Vista Pharmaceuticals' ROCE % too high?
Vista Pharmaceuticals' current ROCE % is -75.10%. Overall, Vista Pharmaceuticals has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vista Pharmaceuticals' ROCE % compare to ZTS and UTHR?
Vista Pharmaceuticals' ROCE % of -75.10% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vista Pharmaceuticals's current ROCE % is -75.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vista Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vista Pharmaceuticals (BOM:524711) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6.05, compared to a current price of ₹7.28 — trading 20.3% above its estimated fair value. The current ROCE % is -75.10%. Vista Pharmaceuticals' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vista Pharmaceuticals (BOM:524711), the current ROCE % is -75.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?

Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued. The current stock price of ₹7.28 is trading 20.3% above its estimated GF Value™ of ₹6.05. GuruFocus considers Vista Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BOM:524711:

  • ROCE %: -75.10%
  • GF Value™: ₹6.05 vs. price of ₹7.28 (20.3% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vista Pharmaceuticals Business Description

Address Kakateeya Hills, Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet, Hyderabad, TG, IND, 500033
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
47GF Score

Get the complete analysis for BOM:524711

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7.28
Price
₹6.05
GF Value